{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:58:11Z","timestamp":1791928691671,"version":"4.3.4"},"reference-count":105,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"8","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2018,7,19]]},"DOI":"10.1167\/iovs.18-24015","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T17:25:56Z","timestamp":1532107556000},"page":"3630","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage"],"prefix":"10.1167","volume":"59","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States"},{"name":"Department of Ophthalmology, Fujian Medical University Union Hospital, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui-Kai","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-xing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Chen","sequence":"additional","affiliation":[{"name":"Charlesson, LLC, Oklahoma City, Oklahoma, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"i1552-5783-59-8-3630-b01","doi-asserted-by":"crossref","unstructured":"Bhutto, IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006; 82: 99\u2013110.","DOI":"10.1016\/j.exer.2005.05.007"},{"key":"i1552-5783-59-8-3630-b02","unstructured":"Li T, Hu A, Li S, et al. KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization. Mol Vis. 2011; 17: 797\u2013803."},{"key":"i1552-5783-59-8-3630-b03","doi-asserted-by":"crossref","unstructured":"Zhang W, Ito Y, Berlin E, Roberts R, Berkowitz BA. Role of hypoxia during normal retinal vessel development and in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2003; 44: 3119\u20133123.","DOI":"10.1167\/iovs.02-1122"},{"key":"i1552-5783-59-8-3630-b04","unstructured":"Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006; 104: 264\u2013302."},{"key":"i1552-5783-59-8-3630-b05","doi-asserted-by":"crossref","unstructured":"Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002; 47 (suppl 2): 253\u2013262.","DOI":"10.1016\/S0039-6257(02)00387-9"},{"key":"i1552-5783-59-8-3630-b06","doi-asserted-by":"crossref","unstructured":"Provis JM, Penfold PL, Cornish EE, Sandercoe TM, Madigan MC. Anatomy and development of the macula: specialisation and the vulnerability to macular degeneration. Clin Exp Optom. 2005; 88: 269\u2013281.","DOI":"10.1111\/j.1444-0938.2005.tb06711.x"},{"key":"i1552-5783-59-8-3630-b07","doi-asserted-by":"crossref","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473: 298\u2013307.","DOI":"10.1038\/nature10144"},{"key":"i1552-5783-59-8-3630-b08","doi-asserted-by":"crossref","unstructured":"Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol. 1992; 36: 373\u2013384.","DOI":"10.1016\/0039-6257(92)90115-A"},{"key":"i1552-5783-59-8-3630-b09","doi-asserted-by":"crossref","unstructured":"Robinson GS, Aiello LP. Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin. 1998; 38: 89\u2013102.","DOI":"10.1097\/00004397-199803820-00007"},{"key":"i1552-5783-59-8-3630-b10","doi-asserted-by":"crossref","unstructured":"Aiello LP, Robert L, Avery PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480\u20131487.","DOI":"10.1056\/NEJM199412013312203"},{"key":"i1552-5783-59-8-3630-b11","unstructured":"Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996; 37: 855\u2013868."},{"key":"i1552-5783-59-8-3630-b12","doi-asserted-by":"crossref","unstructured":"Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 2000; 19: 526\u2013533.","DOI":"10.1097\/00003226-200007000-00025"},{"key":"i1552-5783-59-8-3630-b13","doi-asserted-by":"crossref","unstructured":"Gerhardinger C, McClure KD, Romeo G, Podesta F, Lorenzi M. IGF-I mRNA and signaling in the diabetic retina. Diabetes. 2001; 50: 175\u2013183.","DOI":"10.2337\/diabetes.50.1.175"},{"key":"i1552-5783-59-8-3630-b14","doi-asserted-by":"crossref","unstructured":"Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol. 1997; 124: 521\u2013529.","DOI":"10.1016\/S0002-9394(14)70868-2"},{"key":"i1552-5783-59-8-3630-b15","doi-asserted-by":"crossref","unstructured":"Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004; 82: 557\u2013563.","DOI":"10.1111\/j.1600-0420.2004.00312.x"},{"key":"i1552-5783-59-8-3630-b16","doi-asserted-by":"crossref","unstructured":"Cheng SF, Dastjerdi MH, Ferrari G, et al. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol. 2012; 154: 940\u2013948.","DOI":"10.1016\/j.ajo.2012.06.007"},{"key":"i1552-5783-59-8-3630-b17","doi-asserted-by":"crossref","unstructured":"Bock F, K\u00f6nig Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C. Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmology. 2007; 104: 336\u2013344.","DOI":"10.1007\/s00347-007-1512-2"},{"key":"i1552-5783-59-8-3630-b18","doi-asserted-by":"crossref","unstructured":"Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol. 2010; 88: 862\u2013867.","DOI":"10.1111\/j.1755-3768.2009.01571.x"},{"key":"i1552-5783-59-8-3630-b19","doi-asserted-by":"crossref","unstructured":"Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Intl Suppl. 2000; 77: 113\u2013119.","DOI":"10.1046\/j.1523-1755.2000.07718.x"},{"key":"i1552-5783-59-8-3630-b20","unstructured":"Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996; 74: 819\u2013825."},{"key":"i1552-5783-59-8-3630-b21","doi-asserted-by":"crossref","unstructured":"Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor\/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes. 1998; 47: 401\u2013406.","DOI":"10.2337\/diabetes.47.3.401"},{"key":"i1552-5783-59-8-3630-b22","doi-asserted-by":"crossref","unstructured":"Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118: 445\u2013450.","DOI":"10.1016\/S0002-9394(14)75794-0"},{"key":"i1552-5783-59-8-3630-b23","doi-asserted-by":"crossref","unstructured":"Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995; 92: 905\u2013909.","DOI":"10.1073\/pnas.92.3.905"},{"key":"i1552-5783-59-8-3630-b24","doi-asserted-by":"crossref","unstructured":"Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res. 2004; 79: 623\u2013630.","DOI":"10.1016\/j.exer.2004.07.006"},{"key":"i1552-5783-59-8-3630-b25","unstructured":"Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995; 72: 638\u2013645."},{"key":"i1552-5783-59-8-3630-b26","unstructured":"Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001; 42: 2408\u20132413."},{"key":"i1552-5783-59-8-3630-b27","doi-asserted-by":"crossref","unstructured":"Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology. 2001; 108: 705\u2013710.","DOI":"10.1016\/S0161-6420(00)00663-1"},{"key":"i1552-5783-59-8-3630-b28","doi-asserted-by":"crossref","unstructured":"Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003; 22: 1\u201329.","DOI":"10.1016\/S1350-9462(02)00043-5"},{"key":"i1552-5783-59-8-3630-b29","doi-asserted-by":"crossref","unstructured":"Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol. 2012; 153: 468\u2013473.","DOI":"10.1016\/j.ajo.2011.08.011"},{"key":"i1552-5783-59-8-3630-b30","doi-asserted-by":"crossref","unstructured":"Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol. 1999; 14: 240\u2013248.","DOI":"10.3109\/08820539909069543"},{"key":"i1552-5783-59-8-3630-b31","doi-asserted-by":"crossref","unstructured":"Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997; 46: 1473\u20131480.","DOI":"10.2337\/diab.46.9.1473"},{"key":"i1552-5783-59-8-3630-b32","doi-asserted-by":"crossref","unstructured":"Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999; 48: 1899\u20131906.","DOI":"10.2337\/diabetes.48.10.1899"},{"key":"i1552-5783-59-8-3630-b33","doi-asserted-by":"crossref","unstructured":"Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications. Horm Res. 2000; 53: 53\u201367.","DOI":"10.1159\/000023515"},{"key":"i1552-5783-59-8-3630-b34","doi-asserted-by":"crossref","unstructured":"Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003; 19: 442\u2013455.","DOI":"10.1002\/dmrr.415"},{"key":"i1552-5783-59-8-3630-b35","doi-asserted-by":"crossref","unstructured":"Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001; 489: 270\u2013276.","DOI":"10.1016\/S0014-5793(01)02110-X"},{"key":"i1552-5783-59-8-3630-b36","doi-asserted-by":"crossref","unstructured":"Wu JJ, Huang DB, Pang KR, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005; 153: 254\u2013273.","DOI":"10.1111\/j.1365-2133.2005.06747.x"},{"key":"i1552-5783-59-8-3630-b37","doi-asserted-by":"crossref","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314\u2013322.","DOI":"10.1038\/nrc1323"},{"key":"i1552-5783-59-8-3630-b38","doi-asserted-by":"crossref","unstructured":"Hattori Y, Kakimoto T, Okamoto S, Sato N, Ikeda Y. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Hematol. 2004; 79: 283\u2013288.","DOI":"10.1532\/IJH97.03136"},{"key":"i1552-5783-59-8-3630-b39","doi-asserted-by":"crossref","unstructured":"Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis. 1997; 1: 23\u201335.","DOI":"10.1023\/A:1018301031580"},{"key":"i1552-5783-59-8-3630-b40","doi-asserted-by":"crossref","unstructured":"Bosco AA, Lerario AC, Santos RF, Wajchenberg BL. Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetologia. 2003; 46: 1669\u20131675.","DOI":"10.1007\/s00125-003-1234-1"},{"key":"i1552-5783-59-8-3630-b41","unstructured":"Arne-Bes MC. Neurotoxic effects of medications: an update. Rev Med Liege. 2004; 59 (suppl 1): 118\u2013123."},{"key":"i1552-5783-59-8-3630-b42","doi-asserted-by":"crossref","unstructured":"Pathak RD, Jayaraj K, Blonde L. Thalidomide-associated hyperglycemia and diabetes: case report and review of literature. Diabetes Care. 2003; 26: 1322\u20131323.","DOI":"10.2337\/diacare.26.4.1322-a"},{"key":"i1552-5783-59-8-3630-b43","doi-asserted-by":"crossref","unstructured":"Iqbal N, Zayed M, Boden G. Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes. Diabetes Care. 2000; 23: 1172\u20131176.","DOI":"10.2337\/diacare.23.8.1172"},{"key":"i1552-5783-59-8-3630-b44","doi-asserted-by":"crossref","unstructured":"Xiao Z, Schaefer K, Firestine S, Li PK. Solid-phase synthesis of thalidomide and its analogues. J. Comb. Chem. 2002; 4: 149\u2013153.","DOI":"10.1021\/cc010038n"},{"key":"i1552-5783-59-8-3630-b45","doi-asserted-by":"crossref","unstructured":"Li PK, Pandit B, Sackett DL, et al. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006; 5: 450\u2013456.","DOI":"10.1158\/1535-7163.MCT-05-0254"},{"key":"i1552-5783-59-8-3630-b46","unstructured":"Wong HC, Boulton M, Marshall J, Clark P. Growth of retinal capillary endothelia using pericyte conditioned medium. Invest Opthalmol Vis Sci. 1987; 28: 1767\u20131775."},{"key":"i1552-5783-59-8-3630-b47","doi-asserted-by":"crossref","unstructured":"Lee SH, Kim KW, Joo K, Kim JC. Angiogenin ameliorates corneal opacity and neovascularization via regulating immune response in corneal fibroblasts. BMC Ophthalmol. 2016; 16: 1\u201313.","DOI":"10.1186\/s12886-016-0235-z"},{"key":"i1552-5783-59-8-3630-b48","unstructured":"Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996; 37: 2485\u20132494."},{"key":"i1552-5783-59-8-3630-b49","doi-asserted-by":"crossref","unstructured":"Anderson C, Zhou Q, Wang S. An alkali-burn injury model of corneal neovascularization in the mouse. J Vis Exp. 2014; 86: 1\u20136.","DOI":"10.3791\/51159"},{"key":"i1552-5783-59-8-3630-b50","doi-asserted-by":"crossref","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91: 4082\u20134085.","DOI":"10.1073\/pnas.91.9.4082"},{"key":"i1552-5783-59-8-3630-b51","doi-asserted-by":"crossref","unstructured":"Figueroa-Ortiz LC, Martin Rodriguez O, Garcia-Ben A, Garcia-Campos J. Neovascular growth in an experimental alkali corneal burn model. Arch Soc Esp Oftalmol. 2014; 89: 303\u2013307.","DOI":"10.1016\/j.oftal.2014.02.016"},{"key":"i1552-5783-59-8-3630-b52","unstructured":"Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994; 35: 101\u2013111."},{"key":"i1552-5783-59-8-3630-b53","unstructured":"Shyong MP, Lee FL, Kuo PC, et al. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol Vis. 2007; 13: 133\u2013141."},{"key":"i1552-5783-59-8-3630-b54","unstructured":"Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001; 42: 789\u2013794."},{"key":"i1552-5783-59-8-3630-b55","doi-asserted-by":"crossref","unstructured":"Bae DG, Gho YS, Yoon WH, Chae CB. Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem. 2000; 275: 13588\u201313596.","DOI":"10.1074\/jbc.275.18.13588"},{"key":"i1552-5783-59-8-3630-b56","doi-asserted-by":"crossref","unstructured":"Rohrer B, Korenbrot JI, LaVail MM, Reichardt LF, Xu B. Role of neurotrophin receptor TrkB in the maturation of rod photoreceptors and establishment of synaptic transmission to the inner retina. J Neurosci. 1999; 19: 8919\u20138913.","DOI":"10.1523\/JNEUROSCI.19-20-08919.1999"},{"key":"i1552-5783-59-8-3630-b57","doi-asserted-by":"crossref","unstructured":"Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998; 43: 245\u2013269.","DOI":"10.1016\/S0039-6257(98)00035-6"},{"key":"i1552-5783-59-8-3630-b58","doi-asserted-by":"crossref","unstructured":"Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012; 57: 415\u2013429.","DOI":"10.1016\/j.survophthal.2012.01.007"},{"key":"i1552-5783-59-8-3630-b59","doi-asserted-by":"crossref","unstructured":"Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology. 1983; 90: 1301\u20131317.","DOI":"10.1016\/S0161-6420(83)34388-8"},{"key":"i1552-5783-59-8-3630-b60","doi-asserted-by":"crossref","unstructured":"Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene. 2003; 22: 6537\u20136548.","DOI":"10.1038\/sj.onc.1206773"},{"key":"i1552-5783-59-8-3630-b61","doi-asserted-by":"crossref","unstructured":"Ingeborg K, Cornelis JF, Van N, Reinier OS. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013; 34: 19\u201348.","DOI":"10.1016\/j.preteyeres.2013.02.001"},{"key":"i1552-5783-59-8-3630-b62","unstructured":"Holger G, Matthew G, Marcus F, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003; 16: 1163\u20131177."},{"key":"i1552-5783-59-8-3630-b63","doi-asserted-by":"crossref","unstructured":"Peter C, Rakesh KJ. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249\u2013257.","DOI":"10.1038\/35025220"},{"key":"i1552-5783-59-8-3630-b64","doi-asserted-by":"crossref","unstructured":"Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000; 70: 419\u2013428.","DOI":"10.1006\/exer.1999.0790"},{"key":"i1552-5783-59-8-3630-b65","doi-asserted-by":"crossref","unstructured":"Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013; 7: 4\u201310.","DOI":"10.2174\/1874364101307010004"},{"key":"i1552-5783-59-8-3630-b66","doi-asserted-by":"crossref","unstructured":"Eugene WM, David TS, Perry C, Emmett TC, David RG, Anthony PA. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006; 5: 123\u2013132.","DOI":"10.1038\/nrd1955"},{"key":"i1552-5783-59-8-3630-b67","unstructured":"Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularised human corneas. Invest Ophthalmol Vis Sci. 2000; 41: 2514\u20132522."},{"key":"i1552-5783-59-8-3630-b68","doi-asserted-by":"crossref","unstructured":"Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996; 37: 1929\u20131934.","DOI":"10.1016\/S0002-9394(14)70522-7"},{"key":"i1552-5783-59-8-3630-b69","doi-asserted-by":"crossref","unstructured":"Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol. 1998; 82: 561\u2013568.","DOI":"10.1136\/bjo.82.5.561"},{"key":"i1552-5783-59-8-3630-b70","doi-asserted-by":"crossref","unstructured":"Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007; 41: 614\u2013625.","DOI":"10.1345\/aph.1H316"},{"key":"i1552-5783-59-8-3630-b71","doi-asserted-by":"crossref","unstructured":"Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006; 113: 1522\u20131532.","DOI":"10.1016\/j.ophtha.2006.05.055"},{"key":"i1552-5783-59-8-3630-b72","doi-asserted-by":"crossref","unstructured":"Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol. 2006; 90: 1344\u20131349.","DOI":"10.1136\/bjo.2006.099598"},{"key":"i1552-5783-59-8-3630-b73","doi-asserted-by":"crossref","unstructured":"Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008; 246: 81\u201387.","DOI":"10.1007\/s00417-007-0660-z"},{"key":"i1552-5783-59-8-3630-b74","doi-asserted-by":"crossref","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008; 51: 1574\u20131580.","DOI":"10.1007\/s00125-008-0989-9"},{"key":"i1552-5783-59-8-3630-b75","doi-asserted-by":"crossref","unstructured":"Eugene WM, Anthony PA. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci. 2006; 1082: 151\u2013171.","DOI":"10.1196\/annals.1348.062"},{"key":"i1552-5783-59-8-3630-b76","doi-asserted-by":"crossref","unstructured":"Ong SE, Monica S, Adam A, et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009; 106: 4617\u20134622.","DOI":"10.1073\/pnas.0900191106"},{"key":"i1552-5783-59-8-3630-b77","doi-asserted-by":"crossref","unstructured":"Wan H. An overall comparison of small molecules and large biologics in ADME testing. ADMET DMPK. 2016; 4: 1\u201322.","DOI":"10.5599\/admet.4.1.276"},{"key":"i1552-5783-59-8-3630-b78","doi-asserted-by":"crossref","unstructured":"Li L, Tian D, Chen F, Yang J, Yu K, Sun Y . Strategies for improving the quantitative bioanalytical performance of LC-MS in pharmacokinetic studies. Curr Drug Metab. 2012; 13: 1206\u20131212.","DOI":"10.2174\/138920012803341320"},{"key":"i1552-5783-59-8-3630-b79","doi-asserted-by":"crossref","unstructured":"Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006; 42: 1612\u20131622.","DOI":"10.1016\/j.ejca.2006.04.004"},{"key":"i1552-5783-59-8-3630-b80","doi-asserted-by":"crossref","unstructured":"Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005; 22: 14\u201319.","DOI":"10.1208\/aapsj070103"},{"key":"i1552-5783-59-8-3630-b81","unstructured":"Mujagic H, Chabner BA, Mujagic Z. Mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J. 2002; 43: 274\u2013285."},{"key":"i1552-5783-59-8-3630-b82","unstructured":"Von Moos R, Stolz R, Cerny T, Gillessen S. Thalidomide: from tragedy to promise. Swiss Med Wkly. 2003; 133: 77\u201387."},{"key":"i1552-5783-59-8-3630-b83","doi-asserted-by":"crossref","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91: 4082\u20134085.","DOI":"10.1073\/pnas.91.9.4082"},{"key":"i1552-5783-59-8-3630-b84","doi-asserted-by":"crossref","unstructured":"Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997; 64: 971\u2013978.","DOI":"10.1006\/exer.1997.0292"},{"key":"i1552-5783-59-8-3630-b85","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000; 96: 2943\u20132950.","DOI":"10.1182\/blood.V96.9.2943"},{"key":"i1552-5783-59-8-3630-b86","doi-asserted-by":"crossref","unstructured":"Komorowski J, Jerczynska H, Siejka A, et al. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sciences. 2006; 78: 2558\u20132563.","DOI":"10.1016\/j.lfs.2005.10.016"},{"key":"i1552-5783-59-8-3630-b87","doi-asserted-by":"crossref","unstructured":"Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood. 2005; 106: 125\u2013134.","DOI":"10.1182\/blood-2004-09-3679"},{"key":"i1552-5783-59-8-3630-b88","doi-asserted-by":"crossref","unstructured":"Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993; 177: 1675\u20131680.","DOI":"10.1084\/jem.177.6.1675"},{"key":"i1552-5783-59-8-3630-b89","doi-asserted-by":"crossref","unstructured":"Niwayama S, Turk BE, Liu JO. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem. 1996; 39: 3044\u20133045.","DOI":"10.1021\/jm960284r"},{"key":"i1552-5783-59-8-3630-b90","doi-asserted-by":"crossref","unstructured":"Powers MR, Qu Z, O'Brien B, Wilson DJ, Thompson JE, Rosenbaum JT. Immunolocalization of bFGF in pterygia: association with mast cells. Cornea. 1997; 16: 545\u2013549.","DOI":"10.1097\/00003226-199709000-00010"},{"key":"i1552-5783-59-8-3630-b91","doi-asserted-by":"crossref","unstructured":"Yagyu T, Kobayashi H, Matsuzaki H, et al. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab. 2005; 90: 3017\u20133021.","DOI":"10.1210\/jc.2004-1946"},{"key":"i1552-5783-59-8-3630-b92","unstructured":"Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol. 1998; 25: 53\u201357."},{"key":"i1552-5783-59-8-3630-b93","doi-asserted-by":"crossref","unstructured":"Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996; 31: 213\u2013221.","DOI":"10.1016\/0162-3109(95)00050-X"},{"key":"i1552-5783-59-8-3630-b94","doi-asserted-by":"crossref","unstructured":"Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001; 276: 22382\u201322387.","DOI":"10.1074\/jbc.M100938200"},{"key":"i1552-5783-59-8-3630-b95","doi-asserted-by":"crossref","unstructured":"Noguchi T, Shimazawa R, Nagasawa K, Hashimoto Y. Thalidomide and its analogues as cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2002; 12: 1043\u20131046.","DOI":"10.1016\/S0960-894X(02)00084-7"},{"key":"i1552-5783-59-8-3630-b96","unstructured":"Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003; 1: 194\u2013205."},{"key":"i1552-5783-59-8-3630-b97","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev. 2000; 26: 351\u2013362.","DOI":"10.1053\/ctrv.2000.0188"},{"key":"i1552-5783-59-8-3630-b98","doi-asserted-by":"crossref","unstructured":"Zhang SX, Sima J, Shao C, et al. Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. Diabetologia. 2004; 47: 124\u2013131.","DOI":"10.1007\/s00125-003-1276-4"},{"key":"i1552-5783-59-8-3630-b99","doi-asserted-by":"crossref","unstructured":"Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003; 458: 283\u2013289.","DOI":"10.1016\/S0014-2999(02)02793-0"},{"key":"i1552-5783-59-8-3630-b100","doi-asserted-by":"crossref","unstructured":"Hosseini H, Nejabat MA. Potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses. 2007; 68: 799\u2013801.","DOI":"10.1016\/j.mehy.2006.06.063"},{"key":"i1552-5783-59-8-3630-b101","doi-asserted-by":"crossref","unstructured":"Bock F, Konig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246: 281\u2013284.","DOI":"10.1007\/s00417-007-0684-4"},{"key":"i1552-5783-59-8-3630-b102","doi-asserted-by":"crossref","unstructured":"Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002; 60: 501\u2013509.","DOI":"10.1016\/S0002-9440(10)64869-9"},{"key":"i1552-5783-59-8-3630-b103","doi-asserted-by":"crossref","unstructured":"Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY . Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-?B activation in endothelial cells. J Biol Chem. 2001; 276: 7614\u20137620.","DOI":"10.1074\/jbc.M009705200"},{"key":"i1552-5783-59-8-3630-b104","doi-asserted-by":"crossref","unstructured":"Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000; 156: 1733\u20131739.","DOI":"10.1016\/S0002-9440(10)65044-4"},{"key":"i1552-5783-59-8-3630-b105","doi-asserted-by":"crossref","unstructured":"Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999; 96: 10836\u201310841.","DOI":"10.1073\/pnas.96.19.10836"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?articleid=2688622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:30:55Z","timestamp":1791927055000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.18-24015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":105,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,7,2]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.18-24015","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}